Research Topic: terbinafine

Experimental research on fungal inhibition using dissolving microneedles of terbinafine hydrochloride nanoemulsion for beta-1,3-glucanase

mycolabadmin

Researchers developed a new patch treatment for nail fungus using tiny dissolving needles that deliver antifungal medication directly into the skin near infected nails. The patch combines two active ingredients that work together to kill fungus and break down protective biofilm layers that make fungal infections hard to treat. Testing showed the patch was safe, effective, and delivered much more medication to the infected area compared to traditional creams or pills.

Read More »

Establishment of epidemiological cutoff values for Fonsecaea pedrosoi, the primary etiologic agent of chromoblastomycosis, and eight antifungal medications

mycolabadmin

Chromoblastomycosis is a serious fungal skin infection caused by a fungus called Fonsecaea pedrosoi, particularly affecting people in tropical regions and those in poverty. Researchers from multiple countries tested 148 samples of this fungus against eight different antifungal medications to determine how well each drug works. They established baseline measurements that doctors can use to determine if a patient’s fungal infection might not respond well to standard treatments, helping guide better treatment decisions.

Read More »

Formulation, characterization, and in vitro antifungal evaluation of liposomal terbinafine prepared by the ethanol injection method

mycolabadmin

Researchers developed a new way to deliver the antifungal drug terbinafine using tiny fat-based particles called liposomes. These particles are designed to carry the drug more effectively to infected tissues while reducing harmful side effects. The optimized formulation showed promise for treating stubborn fungal infections, especially those affecting the brain, with significantly reduced toxicity compared to the drug alone.

Read More »
Scroll to Top